financial guidance

The firm's revenues in Asia were up compared to a year ago, but the coronavirus pandemic drove down revenues in the US, Europe, and the rest of the world.

The firm's subsidiary BioReference Laboratories performed 3.5 million COVID-19 PCR tests and 300,000 serology tests during the quarter.

Bio-Rad's year-over-year Q3 revenue increase was driven primary by sales of PCR and Droplet Digital PCR products due to the COVID-19 pandemic.

GenMark said it placed 70 net ePlex analyzers in Q3 and ended the quarter with a global installed base of more than 720 ePlex analyzers.

Qiagen said that growth in the quarter was primarily driven by COVID-19 testing products and improving customer demand for other products.

The firm said that its core business, excluding COVID-19 clinical testing revenues, returned to positive organic growth in the quarter.

The revenue increase was driven by significant growth in the conglomerate's life sciences segment.

The company reported net income of $1.93 billion, or $4.84 per share, compared to $760 million, or $1.89 per share, for the year-ago quarter.

The firm's variety of COVID-19 molecular and immunoassay test offerings offset declines in the point-of-care segment.